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EDITORIAL
The paper on Medscheme’s generic medicines reference pricing
initiative reported in this issue of the SAMJ1 (p. 183) raises
several questions. At the time of introduction, the merits and
demerits of the so-called ‘Medicine Price List’ were hotly
debated in the lay press, on radio and even on national
television.
Has this initiative influenced quality of care in a positive or
negative way?  If quality of care is defined as the appropriate,
cost-effective use of resources within the limits of what is
affordable, evidence seems to indicate a positive effect.
Did this initiative have a deleterious effect on the financial
livelihood of any of the stakeholders in health care? The
answer is difficult to quantify, but it seems as if the competition
introduced between manufacturers of generic equivalent drugs
was healthy and patients were better off. Because of the lower
price paid by consumers for generically equivalent drugs, their
benefits or budgets could stretch further. This also made life
easier for doctors and pharmacists.
The more serious question, however, is the way forward. The
way in which medicine is allowed to be practised by a society
is influenced by a complex interplay of economic, social and
political factors. The volatility and sensitivity of the current
South African situation is demonstrated by the recent march on
parliament of a representative group of doctors.
The patient’s perspective on health care into the future is the
most important. Simply put, it is the common and collective
duty of all stakeholders to find a way to balance access with
cost and quality for the entire population. Self interest is less
important. Confrontation and adherence to outdated policies,
practices and procedures are counterproductive.
Rapidly promulgated new legislation and regulation
addresses key issues of equity and community. Government
will not allow a system that provides the poor, elderly and
chronically sick (both in the public and private sectors) with
inferior funding and therefore services. When measured in
terms of standards of delivery against cost, the social-
democratic measures being introduced are aimed at being more
efficient for the larger population. The economically strong will
share with the less fortunate to guarantee efficiency and equity.
While medical leaders (of all categories of ‘providers’ of care)
are negotiating with government, practitioners are feeling
desperately squeezed between the advance of these social-
democratic measures, the demands of patients, and the ever-
dwindling benefits that these patients (in private practice) can
afford, despite contribution increases that outstrip the
consumer price index. In order to manage this situation,
medical schemes are prioritising benefits, which means that
reimbursement rules (for many options) are complex, placing
an administrative function on practitioners.
Another important focus of disquiet involves limitation on
access to new technology, due to financial constraints. In order
for practitioners to pursue their modern-day trade optimally,
they need access to sophisticated equipment and medicines.
Short of banning research and development, growth of costly
advances will not be contained. Some of these advances are
also cost-effective in absolute terms; in other words, total
health care costs will decrease due to their (expensive) use.
Others are relatively cost-effective; good value for money, but
still unaffordable in the bigger scheme of things.
These complex issues and questions can, however, be
resolved. In many instances they are already being addressed.
A policy of patient-focused prioritisation of benefits as the
basis for reimbursement rules provides the solution.
These rules have to be explicitly transparent and defensible
on scientific, financial and ethical grounds.
The true answer lies in collaboration of stakeholders,
including government and pharmaceutical industry.
Large pools of quality data are analysed to assess clinical and
financial risk of relevant South African populations. Results are
used to introduce appropriate delivery and funding models.
Meaningful risk-sharing and strategic partnerships are
essential.
The depth of clinical and actuarial resources in our country
must be utilised to balance costs with access to, and quality of,
patient care.
The cost issue has been squarely addressed by  the
Medicines Control Amendment Act (Act 90 of 1997), but with
the fundamental aim of providing access to the same medicines
at a lower price. To this end a Pricing Committee was set up in
2003 to develop a system to support and enhance the
requirements of the Act.  Recently published recommendations
of the Committee were:
• the introduction of a single exit price for all medicines and
scheduled substances
• determination of an appropriate dispensing fee to be charged
by pharmacists or any person licensed to do so in terms of
the Act 
• determination of an appropriate fee to be charged by the
wholesalers or distributors or any person selling medicines
that do not require a prescription. 
The draft Regulations introducing these measures were
published by the Department of Health on 16 January 2004.
These regulations are open for public comment for a period of
3 months as from 16 January 2004 and are to be enacted, with
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adjustments, on 2 May 2004.  
It is expected that the proposed single exit price, pegged at a
minimum of 50% of the manufacturer’s net price, will be
vigorously contested by the pharmaceutical manufacturers.
However, while there may well be adjustments to this figure,
the costs of medicines will almost certainly decrease with this
new legislation.  The draft Regulations also regulate price
increases, thereby hedging traditional risk due to year-on-year
medicines price increases, and not only will price increases be
regulated against CPI and PPI figures, but local prices will be
also be compared to international equivalent prices and
comparator products.  The Regulations do not make any
reference to control in terms of launch price of new products
introduced into the market, but the originator product at 50%
of the current cost would effectively ‘ceiling’ the price for
generic entries post patent expiry.  
The proposed legislation fixes the price of a product and
pack size for one year (only downward adjustments are
allowed in this time), but large price variations are expected to
remain for groups of products used to treat a disease.  The
likelihood is that the Act and proposed Regulations, while
promoting generic substitution, will still permit substitution by
the highest priced equivalent, and where the mark-up is
expressed as a percentage of the manufacturer’s exit price one
can expect to see dispensing of the product which will
maximise dispenser’s margins.
Taking the above into account, the question might be asked
whether medicine management programmes will still be
relevant within the medical schemes environment. Reference to
the paper by Kanavos2 which is summarised in this issue of the
Journal1 suggests that there is indeed a place for supply-side
management as well as for demand and proxy-demand
management. The managed care programmes introduced to
medical schemes address cost and utilisation factors, both of
which remain relevant for the future. As a result, the generic
medicines reference pricing model, as described in this issue of
the Journal,1 will most likely remain as an option selected by
trustees of medical schemes. 
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